Lopez et al., 2025 - Google Patents
Autogene cevumeran with or without atezolizumab in advanced solid tumors: a phase 1 trialLopez et al., 2025
View HTML- Document ID
- 2691934240486833731
- Author
- Lopez J
- Powles T
- Braiteh F
- Siu L
- LoRusso P
- Friedman C
- Balmanoukian A
- Gordon M
- Yachnin J
- Rottey S
- Karydis I
- Fisher G
- Schmidt M
- Schuler M
- Sullivan R
- Burris H
- Galvao V
- Henick B
- Dirix L
- Jaeger D
- Ott P
- Wong K
- Jerusalem G
- Schiza A
- Fong L
- Steeghs N
- Leidner R
- Rittmeyer A
- Laurie S
- Gort E
- Aljumaily R
- Melero I
- Sabado R
- Rhee I
- Mancuso M
- Muller L
- Fine G
- Yadav M
- Kim L
- Leveque V
- Robert A
- Darwish M
- Qi T
- Zhu J
- Zhang J
- Twomey P
- Rao G
- Low D
- Petry C
- Lo A
- Schartner J
- Delamarre L
- Mellman I
- Löwer M
- Müller F
- Derhovanessian E
- Cortini A
- Manning L
- Maurus D
- Brachtendorf S
- Lörks V
- Omokoko T
- Godehardt E
- Becker D
- Hawner C
- Wallrapp C
- Albrecht C
- Kröner C
- Tadmor A
- Diekmann J
- Vormehr M
- Jork A
- Paruzynski A
- Lang M
- Blake J
- Hennig O
- Kuhn A
- Sahin U
- Türeci Ã
- Camidge D
- Publication year
- Publication venue
- Nature Medicine
External Links
Snippet
Effective targeting of somatic cancer mutations to enhance the efficacy of cancer immunotherapy requires an individualized approach. Autogene cevumeran is a uridine messenger RNA lipoplex-based individualized neoantigen-specific immunotherapy …
- 229940053956 autogene cevumeran 0 title abstract description 131
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay
- G01N33/574—Immunoassay; Biospecific binding assay for cancer
- G01N33/57407—Specifically defined cancers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Hybridisation probes
- C12Q1/6883—Hybridisation probes for diseases caused by alterations of genetic material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Rojas et al. | Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer | |
| Ding et al. | Personalized neoantigen pulsed dendritic cell vaccine for advanced lung cancer | |
| Genova et al. | Therapeutic implications of tumor microenvironment in lung cancer: focus on immune checkpoint blockade | |
| Puig-Saus et al. | Neoantigen-targeted CD8+ T cell responses with PD-1 blockade therapy | |
| Hu et al. | Personal neoantigen vaccines induce persistent memory T cell responses and epitope spreading in patients with melanoma | |
| Luke et al. | KEYNOTE-716: Phase III study of adjuvant pembrolizumab versus placebo in resected high-risk stage II melanoma | |
| DeFalco et al. | Non-progressing cancer patients have persistent B cell responses expressing shared antibody paratopes that target public tumor antigens | |
| Ogino et al. | Randomized trial of neoadjuvant vaccination with tumor-cell lysate induces T cell response in low-grade gliomas | |
| US20180291074A1 (en) | Determinants of cancer response to immunotherapy by pd-1 blockade | |
| Sillo et al. | Mechanisms of immunogenicity in colorectal cancer | |
| Yarchoan et al. | Personalized neoantigen vaccine and pembrolizumab in advanced hepatocellular carcinoma: a phase 1/2 trial | |
| Radvanyi | Tumor-infiltrating lymphocyte therapy: addressing prevailing questions | |
| Saberian et al. | Randomized phase II trial of lymphodepletion plus adoptive cell transfer of tumor-infiltrating lymphocytes, with or without dendritic cell vaccination, in patients with metastatic melanoma | |
| US20220152176A1 (en) | Cancer biomarkers for durable clinical benefit | |
| Tazzari et al. | Adaptive immunity in fibrosarcomatous dermatofibrosarcoma protuberans and response to imatinib treatment | |
| AU2018379094A1 (en) | Phenotypic markers for cell therapy and related methods | |
| US20230223105A1 (en) | Mitigation of statistical bias in genetic sampling | |
| US20190284640A1 (en) | Methods and Systems for Predicting Response to Immunotherapies for Treatment of Cancer | |
| US20230135171A1 (en) | Methods and systems for molecular disease assessment via analysis of circulating tumor dna | |
| Hubbard et al. | Safety and activity of PolyPEPI1018 combined with maintenance therapy in metastatic colorectal cancer: an open-label, multicenter, phase Ib study | |
| Altorki et al. | Neoadjuvant durvalumab plus radiation versus durvalumab alone in stages I–III non-small cell lung cancer: survival outcomes and molecular correlates of a randomized phase II trial | |
| Pizzolla et al. | Tissue-resident memory T cells from a metastatic vaginal melanoma patient are tumor-responsive T cells and increase after anti-PD-1 treatment | |
| Penter et al. | Personal tumor antigens in blood malignancies: genomics-directed identification and targeting | |
| JP2024511166A (en) | Targeted therapy for cancer | |
| EP4291902A2 (en) | Biomarkers for cancer treatment |